Actionable Genomic Intelligence for R&D clients
With the advent of new developments of drug combinations and targeted treatments, the ability to stratify patient populations for clinical trial accuracy has become increasingly important. Specifically, BIOARRAY’s biomarker platform can be used as a framework to stratify categories of patients, select patients for clinical trials, and develop companion diagnostic by providing a more in-depth and comprehensive view of gene expression profiles and key cellular signaling pathways.
BIOARRAY selected a unique panel of 300+ oncology biomarkers using a biology-based approach.
BIOARRAY’s biomarker platform is not only different from other cancer biomarker panels, but its unique biomarkers enhance the coverage of cell signaling pathways that are poorly represented in other panels. Broader pathways provide vital information about mechanism of action and cancer response.
BIOARRAY has developed technically validated assays for 300+ RNA-biomarkers to measure gene expression profiles in two widely used technology platforms.
The assays covering BIOARRAY’s panel of 300+ genes are currently available in conjunction with the company’s proprietary algorithms for research and development projects.
– Nanostring’s n-counter custom assay for 325 RNA-biomarkers
– Affymetrix chips (Human U133A Plus 2.0)
– FFPE biopsy
– Frozen biopsy
– Cell lines
BIOARRAY’s Lead Predictive Test BA100
The Company’s lead test, BA100, predicts the likelihood that a breast cancer patient will achieve pathological complete response (pCR) as a result of standard-of-care anthracyline/taxane neoadjuvant chemotherapy. The test results encompass quantitative probability scores and accurate personalized information that can help doctors and patients determine the optimal course of treatment.
The candidates for this test are newly diagnosed breast cancer patients with locally advanced disease, independent of lymph node status or subtype, that are eligible for neoadjuvant chemotherapy.
BIOARRAY’s ongoing research and technology development efforts are aimed at expanding the impact of molecular information to guide the treatment of other types of cancer in addition to our current test for invasive breast cancer. The cancer treatment paradigm is evolving rapidly, and BIOARRAY is an integral part of that evolution.